2026-04-29T12:24:04Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/172442024-11-28T15:52:37Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16938
Repisalud
author
Carrasco-Antón, Nerea
author
Ibarra-Meneses, Ana Victoria
author
Carrillo, Eugenia
author
Fernández-Ruiz, Mario
author
Hernández-Jiménez, Pilar
author
Aguado, José María
author
Moreno, Javier
author
López-Medrano, Francisco
funder
World Health Organization (WHO/OMS)
funder
Ministerio de Ciencia y Universidades (España)
funder
Instituto de Salud Carlos III
funder
RETICS-Investigación colaborativa en Enfermedades Tropicales (RICET-ISCIII) (España)
funder
Plan Nacional de I+D+i (España)
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
funder
Ministerio de Ciencia e Innovación (España)
2024-01-22T08:43:51Z
2024-01-22T08:43:51Z
2022-04
J Infect. 2022 Apr;84(4):573-578.
10.1016/j.jinf.2022.01.029
1532-2742
The Journal of infection
35101535
http://hdl.handle.net/20.500.12105/17244
Objective: Sensitive and less laborious assays are needed to detect asymptomatic Leishmania among solid organ transplant (SOT) recipients. Using SLA-stimulated plasma from SOT recipients living where an outbreak of Leishmania infantum occurred, we examined potential biomarkers to identify asymptomatic Leishmania infections. Methods: Concentrations of cytokines/chemokines in plasma from whole blood stimulated with specific Leishmania antigen (SLA) were compared against infection status as determined by a currently used cell proliferation assay. Results: Twenty-six percent (13/50) of the SOT recipients had a cell proliferation assay (CPA) indicating asymptomatic infection, and showed higher processed plasma C-X-C motif chemokine ligand 10 (CXCL10 or IP-10) concentrations than did non-infected subjects (median 2272.0 pg/ml [IQR 1570-2772] vs. 18.2 pg/ml [IQR 1-150.1]; p<0.0001). CXCL10 showed a sensitivity of 93% and a specificity of 95% compared to CPA. In addition, we demonstrated that the number of asymptomatic infections detected using CXCL10, decreased with distance from a park at the center of the mentioned outbreak. Conclusion: CXCL10 in plasma from SLA-stimulated blood could be a robust biomarker of asymptomatic L. infantum infection in solid organ transplant recipients.
eng
SSolid-organ transplant recipients
Leishmania
Leishmaniasis
Biomarkers
Asymptomatic infection
IP-10
CXCL10
An exploratory analysis of C-X-C motif chemokine ligand 10 as a new biomarker of asymptomatic Leishmania infantum infection in solid-organ transplant recipients
review article
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
URL
https://repisalud.isciii.es/bitstreams/601c0b5a-c72f-48d0-9374-978db5c07c57/download
File
MD5
be2e69adee42d776792b5272a128517b
1110827
application/pdf
Analysis_C-X-C_MotifChemokine_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/86c3aa20-1220-41d8-aa07-ba53d9b3cc85/download
File
MD5
4b56db025b19ef715ea001acb24e2888
9762
application/pdf
Table1_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/5e715fa0-4942-4d08-a459-11c8d999f444/download
File
MD5
04fa0984d29dd928b165fcaec9469a16
378713
application/pdf
Table2_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/88def5af-2db8-456e-a7dd-93c26a070ceb/download
File
MD5
4653cedf6d8750c3388b3287b15c552e
461738
application/pdf
Table3_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/8bcc220d-6d64-4c06-9a7f-ebdbbbda2f79/download
File
MD5
3c657fa542d77b099a02eed778d43c17
648258
image/tiff
Fig1_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.tif
URL
https://repisalud.isciii.es/bitstreams/4a010316-3597-4ea4-a1bc-c6361195c1cd/download
File
MD5
a72c9997dcdccb4653d60065bee7a677
14930408
image/tiff
Fig2_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.tif
URL
https://repisalud.isciii.es/bitstreams/3b92b6c2-2bff-4fac-abfe-33a18ede1013/download
File
MD5
cf79b41e0e670f5fd63ba356d50e09b5
268875
application/pdf
Appendix_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf
URL
https://repisalud.isciii.es/bitstreams/0f07e05e-0f39-4c2c-a3f7-ec1fad09add3/download
File
MD5
c63639ecec214546a831e73656ee69fe
28816
text/plain
ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/df9a7f9a-a98b-443f-af22-c054d17c4e59/download
File
MD5
233b3f0bac2334cca58966b47c51e05c
771
text/plain
Table1_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/9f1b5bfc-d2df-409f-934f-eccf9d12008f/download
File
MD5
673e86d3fe66bde2d003354a6cc8dce8
1507
text/plain
Table2_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/bf3899ec-a65f-4050-829b-4c4368d4eed6/download
File
MD5
6b63a2bef1283a44a6810337fb90145c
983
text/plain
Table3_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/95bf079e-1b30-4618-a1d1-c8b99a7105b0/download
File
MD5
33f9ce067873aeb2562a75450ea0b02e
2846
text/plain
Appendix_ExploratoryAnalysis_C-X-C_MotifChemokine_2022.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/52971779-7dda-40ec-ad79-8493615f16c7/download
File
MD5
51d215551035989fa9fdf189bc2d0ce6
29378
text/plain
Analysis_C-X-C_MotifChemokine_2022.pdf.txt